Acro Biomedical Co Stock Performance
| ACBM Stock | USD 0.0007 0.00 0.00% |
The firm shows a Beta (market volatility) of -0.32, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning ACRO Biomedical are expected to decrease at a much lower rate. During the bear market, ACRO Biomedical is likely to outperform the market. At this point, ACRO Biomedical has a negative expected return of -0.48%. Please make sure to confirm ACRO Biomedical's information ratio, skewness, as well as the relationship between the Skewness and day median price , to decide if ACRO Biomedical performance from the past will be repeated in the future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days ACRO Biomedical Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's fundamental drivers remain very healthy which may send shares a bit higher in August 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 18.1 K |
ACRO |
ACRO Biomedical Relative Risk vs. Return Landscape
If you would invest 0.10 in ACRO Biomedical Co on April 22, 2025 and sell it today you would lose (0.03) from holding ACRO Biomedical Co or give up 30.0% of portfolio value over 90 days. ACRO Biomedical Co is currently does not generate positive expected returns and assumes 3.81% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of pink sheets are less volatile than ACRO, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ACRO Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ACRO Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as ACRO Biomedical Co, and traders can use it to determine the average amount a ACRO Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.127
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ACBM |
Estimated Market Risk
| 3.81 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ACRO Biomedical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ACRO Biomedical by adding ACRO Biomedical to a well-diversified portfolio.
ACRO Biomedical Fundamentals Growth
ACRO Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of ACRO Biomedical, and ACRO Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ACRO Pink Sheet performance.
| Return On Equity | -29.78 | |||
| Return On Asset | -15.5 | |||
| Operating Margin | (17.61) % | |||
| Current Valuation | 240.18 M | |||
| Shares Outstanding | 60.04 M | |||
| Price To Book | 487.98 X | |||
| Price To Sales | 267.90 X | |||
| Revenue | 1.2 M | |||
| EBITDA | (7.69 M) | |||
| Cash And Equivalents | 12.11 K | |||
| Total Debt | 59.44 K | |||
| Debt To Equity | 0.10 % | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | 299.33 K | |||
| Earnings Per Share | (0.20) X | |||
| Total Asset | 761.08 K | |||
About ACRO Biomedical Performance
By examining ACRO Biomedical's fundamental ratios, stakeholders can obtain critical insights into ACRO Biomedical's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that ACRO Biomedical is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products. Acro Biomedical Co., Ltd. was incorporated in 2014 and is based in Fishers, Indiana. Acro Biomedical operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about ACRO Biomedical performance evaluation
Checking the ongoing alerts about ACRO Biomedical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for ACRO Biomedical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ACRO Biomedical generated a negative expected return over the last 90 days | |
| ACRO Biomedical has some characteristics of a very speculative penny stock | |
| ACRO Biomedical has high historical volatility and very poor performance | |
| ACRO Biomedical has high likelihood to experience some financial distress in the next 2 years | |
| About 50.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: INVESTOR ALERT Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX |
- Analyzing ACRO Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ACRO Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining ACRO Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ACRO Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ACRO Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ACRO Biomedical's pink sheet. These opinions can provide insight into ACRO Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in ACRO Pink Sheet
ACRO Biomedical financial ratios help investors to determine whether ACRO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ACRO with respect to the benefits of owning ACRO Biomedical security.